Final answer:
Rituxan (rituximab) is the monoclonal antibody that binds to cell surface proteins of non-Hodgkin's lymphomas(option d). It specifically targets the CD20 protein found on the surface of B cells. Trastuzumab and Bevacizumab are targeted for other purposes and not suitable for NHL treatment.
Step-by-step explanation:
Antibody for Non-Hodgkin's Lymphomas
The specific antibody that is designed to bind to cell surface proteins of non-Hodgkin's lymphomas (NHL) is Rituxan (rituximab). Rituximab is a monoclonal antibody that targets CD20, a protein primarily found on the surface of B cells, including those that can become cancerous in NHL. By binding to CD20, rituximab facilitates the immune system's ability to recognize and destroy these cancerous B cells.
While trastuzumab (Herceptin) is also a monoclonal antibody, it is specifically designed to target HER2, a cell-surface receptor overexpressed in certain types of breast cancer. Therefore, trastuzumab is not used for the treatment of NHL. Bevacizumab targets vascular endothelial growth factor (VEGF) and is used in the treatment of various cancers by inhibiting angiogenesis. However, bevacizumab is not the correct answer in this context as it does not target cell-surface proteins specific to NHL.
Hence, the answer is option d.